NCT07305142Completed
Comparison of the Integrated Posterior-Anterior-Lateral Approach and the Posterior Approach in Robotic Radical Prostatectomy
A Prospective, Randomized Controlled Study Comparing the Integrated Posterior-Anterior-Lateral (PAL) Approach and the Posterior Approach in Robot-Assisted Radical Prostatectomy: Evaluation of Perioperative Outcomes, Postoperative Functional Recovery, and Oncologic Control
Source: ClinicalTrials.gov · Last updated 26 Dec 2025
Brief summary (registry, in English)
This study aims to compare perioperative, pathological, and early functional outcomes of PAL （Posterior, Anterior and Lateral）combined approach RARP and posterior approach (with Retzius space preserved) RARP in the treatment of prostate cancer.The main question it aims to answer was: What is the early therapeutic efficacy of robot-assisted laparoscopic radical prostatectomy using the combined posterior, anterior, and lateral (PAL) approach, and how does it compare with the traditional posterior approach? Participants were randomly assigned to undergo either robot-assisted laparoscopic radical prostatectomy using the PAL (posterior-anterior-lateral) approach or the classic posterior approach.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 2 Dec 2025
- Start date
- 16 May 2024
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- The First Affiliated Hospital of Zhengzhou University
- NCT number
- NCT07305142
What you commit to
- Study type: Interventional
- Participants enrolled: 60
- From 16 May 2024 to the primary completion date, 1 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Urinary incontinence before surgery;
- Previous endoscopic prostate surgery;
Other illness
- There are serious underlying diseases that cannot tolerate surgery or have a survival of less than 5 years;
- Metastatic disease is present or lymph node involvement is suspected at diagnosis;
Other
- Patients judged by the investigator to be unsuitable for participation in this clinical trial;
Who the study is looking for
- Prostate biopsy confirms prostate cancer;
- Clinical T stage \<=T3a stage;
- Fully understand clinical trial protocols and sign informed consent;
Age in the registry: 40 years to 80 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Zhengzhou University Coordinator of this site? Confirm its status | Zhengzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.